Our news

  • Dear colleagues, members, supporters, and friends,It is with considerable regret that Cochrane’s Governing Board announces the cancellation of Cochrane Colloquium Toronto which had been rescheduled for 11-14th September, 2022. The Governing Board recently reviewed an options paper exploring a range of proposals for holding the planned...
    September 14 2021
  • September is Polycystic Ovary Syndrome Awareness Month and is an excellent time to focus on the latest Cochrane evidence.Polycystic ovary syndrome (PCOS) is a common condition affecting 8% to 13% of women in reproductive age. There are three main PCOS featuresmenstrual cycle problems, such as irregular periods or having no periods (meaning...
    September 13 2021
  • Cochrane Convenes will bring together key thought leaders from around the world to discuss the COVID-19 evidence response and develop recommendations to help prepare for and respond to future global health emergencies.In this interview, Cochrane Convenes talks to Jeremy Grimshaw, a member of the Cochrane Convenes steering group, about what he...
    September 8 2021
  • The burden of symptoms at the end of life of COVID-19 patients and helpful treatmentsCOVID-19 patients may show symptoms such as breathlessness or delirium at the end of life. The goal of palliative medicine is to relieve such symptoms with specific treatments. Treatments can be drugs, for example opioids, or non-drugs, such as breathing...
    August 30 2021
  • Readable, clinically-focused, actionable answers to inform point-of-care decision-making for health professionals. Cochrane Clinical Answers (CCAs) provide a readable, digestible, clinically-focused entry point to rigorous research from Cochrane Reviews. They are designed to be actionable and to inform point-of-care decision-making. Each CCA...
    August 20 2021
  • Key messagesThe authors of this Cochrane systematic review, published today by Cochrane’s Infectious Diseases Group, found no evidence to support the use of ivermectin for treating or preventing COVID-19 infection, but the evidence base is limited.Evaluation of ivermectin is continuing in 31 ongoing studies; the authors will update this review...
    August 9 2021
  • The Cochrane Methods team has defined a programme of work to improve the quality and impact of Cochrane reviews in public health with the support of the Methods Executive, Methods Groups and Public Health and Health Systems Network. The programme has been designed to foster collaboration between Methods Groups and...
    August 2 2021
  • Have your say on the Cochrane Convenes programme by filling in a short questionnaireCochrane Convenes is an online event hosted by Cochrane and co-organized with the World Health Organization and the COVID-19 Evidence Network to support Decision making (COVID-END) in October 2021. Drawing on experiences...
    July 26 2021
  • The INGUIDE Program is a comprehensive, evidence-based, and up-to-date training program for guideline recommendation and development. It is the product of a partnership between GIN and world-renowned experts in guideline research, development, and implementation at McMaster University’s Department of Health Research Methods, Evidence, and...
    July 12 2021
  • In 2020, Cochrane’s editorial response to COVID-19 pandemic brought together collaborations across our global organization to publish reviews addressing stakeholder needs as they emerged. Large, highly organized review teams worked together to produce evidence addressing priorities in treatment, prevention, and diagnostics.  In 2021, Cochrane...
    June 18 2021

Pages

      

Subscribe to Our news